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Summary
 
Adenosine (Ado) has been shown to suppress several functional responses of human polymor-
phonuclear leukocytes (PMNs). The current study investigated whether endogenous Ado reg-
ulates the biosynthesis of leukotriene (LT)B
 
4
 
 in ligand-stimulated PMNs. Measurements of Ado in
PMN resuspended in Hanks’ buffered salt solution (HBSS) or plasma showed a cell concentra-
tion– and time–dependent accumulation of the nucleoside. The removal of endogenous Ado with
either Ado deaminase or the blockade of its action by the Ado A
 
2a
 
 receptor antagonist, 8-(3-chlo-
rostyryl) caffeine, markedly increased LTB
 
4
 
 biosynthesis upon ligand stimulation in HBSS. Similarly,
LTB
 
4
 
 synthesis by ligand-stimulated PMNs in plasma (containing recombinant LTA
 
4
 
 hydrolase
to allow the conversion of protein-bound LTA
 
4
 
) was strongly enhanced by addition of Ado deami-
nase. Addition of red blood cells to suspensions of PMNs in plasma mimicked the effect of adding
Ado deaminase and LTA
 
4
 
 hydrolase in enhancing LTB
 
4
 
 biosynthesis upon ligand stimulation.
This effect of red blood cells on LTB
 
4
 
 biosynthesis was blocked by dipyridamole, an inhibitor
of Ado transport, or captopril, an inhibitor of LTA
 
4
 
 hydrolase. These results demonstrate that
endogenous Ado efficiently downregulates ligand-stimulated LTB
 
4
 
 biosynthesis in PMN sus-
pensions, pointing out a potentially important regulatory function of Ado in inflammatory exudates.
These results also unveil a dual role for red blood cells in upregulating LTB
 
4
 
 biosynthesis,
namely, the removal of endogenous Ado and the conversion of LTA
 
4
 
 released by activated PMNs.
 
L
 
eukotriene (LT)
 
1
 
 B
 
4
 
 is a biologically active mediator of
inflammatory processes; indeed, LTB
 
4
 
 is a potent acti-
vator of leukocyte functions, and in particular, is a potent
chemokinetic and chemotactic agent for neutrophils,
monocytes, and macrophages. PMNs, mast cells, mono-
cytes, macrophages, and B lymphocytes are the main cell
types possessing the 5-lipoxygenase (5-LO) and LTA
 
4
 
-con-
verting enzymes and can thus directly produce LTB
 
4
 
 from
endogenous arachidonic acid (1, 2). In blood, PMNs have
been found to be the predominant cell producing LTB
 
4
 
 (3–
5). Interestingly, it was recently demonstrated that activated
PMNs release directly in the extracellular milieu a large
proportion of the LTA
 
4
 
 generated (6); such release of LTA
 
4
 
by PMNs points to the potential importance of transcellular
metabolism in the biosynthesis of the biologically active
metabolites of LTA
 
4
 
, LTB
 
4
 
, and LTC
 
4
 
. Thus, many cell
types present in the neutrophil environment that do not
express the 5-LO, such as endothelial cells, RBCs, T cells,
and platelets, likely constitute important factors in the dy-
namics of LT synthesis in vivo (3, 7–9).
Adenosine (Ado) is a ubiquitous autacoid with a large
spectrum of biological activities, including the modulation
of leukocyte functions. Indeed, numerous studies have re-
ported that acting via Ado A
 
2
 
 receptors, Ado suppressed
PMN functions such as superoxide anion synthesis, adhe-
sion, and phagocytosis, as well as the synthesis of inflamma-
tory cytokines in monocytes. In addition, numerous studies
have also demonstrated that endogenous Ado, as well as
exogenous Ado or Ado analogues, exert antiinflammatory
effects in vivo in animal models (for a review see reference
10). For these reasons, Ado has recently been proposed to
act as an endogenous antiinflammatory agent (10).
In agreement with this concept, we demonstrated in a
previous study that Ado and Ado analogues are very potent
inhibitors of the biosynthesis of LTB
 
4
 
 both in whole blood
and isolated PMNs stimulated with physiological agents
(11). Because it is well established that Ado accumulates in
leukocyte suspensions (as a consequence of the extracellular
breakdown of ATP; reference 12) where its accumulation
reaches a concentration that exerts suppressive effects on
PMN functions, we sought to determine the putative role
of endogenous Ado in regulating LTB
 
4
 
 biosynthesis by
ligand-activated PMNs in various environments.
 
Materials and Methods
 
Materials.
 
Ado deaminase (EC 3.5.4.4., calf intestinal type
VIII), captopril, dipyridamole, 
 
N
 
-formyl-Met-Leu-Phe (fMLP),
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and LPS (
 
Escherichia coli
 
 01110B4) were from Sigma Chemical Co.
(St. Louis, MO). Ado deaminase was dialyzed against NaCl 0.9%
before use. 2-
 
p
 
-(carboxyethyl)phenetylamino-5
 
9
 
-
 
N
 
-ethyl-car-
boxamido-adenosine HCl (CGS 21680) and 8-(3-chlorostyryl)
caffeine (CSC) were from Research Biochemicals International
(Natick, MA). 5
 
9
 
(
 
N
 
-ethyl)carboxamidoadenosine (NECA) was
from ICN Biomedicals Canada Ltd. (Mississauga, Canada). rLTA
 
4
 
hydrolase was obtained from Sf9 cells infected with LTA
 
4
 
 hydro-
lase using the baculovirus system (13). The 100,000 
 
g
 
 supernatant
of infected Sf9 cells was used directly as the source of LTA
 
4
 
 hy-
drolase and contained a specific activity of 60 nmol LTB
 
4
 
/mg of
protein (12 mg of protein/ml). The 100,000 
 
g
 
 supernatant of the
wild-type Sf9 cells (uninfected cells) was used as control. Recom-
binant GM-CSF and TNF-
 
a
 
 were provided by the Genetics In-
stitute (Cambridge, MA) and Knoll Pharmaceuticals (Whippany,
NJ), respectively.
 
Cells.
 
Human PMNs were isolated as previously described
(4). In brief, human venous peripheral blood was collected into
heparinized tubes. RBCs were allowed to sediment at 1 
 
g
 
 after
mixing 4 volumes of blood and 1 volume of dextran 2% in
HBSS. Mononuclear cells were removed by centrifugation on Fi-
coll-Paque cushions. Contaminating RBCs in the PMN pellet
were eliminated by a 20-s hypotonic lysis in water. PMNs were
resuspended in 10 mM Hepes-buffered HBSS (pH 7.4) contain-
ing 1.6 mM CaCl
 
2
 
. RBCs obtained from dextran sedimentation
were freed of contaminating leukocytes by repeated removal of
the buffy coat after four successive centrifugations (200 
 
g
 
, 15 min
at 20
 
8
 
C) and resuspensions in four volumes of 10 mM Hepes-
buffered HBSS (pH 7.4) containing 1.6 mM CaCl
 
2
 
. In some ex-
periments, RBCs were treated with 1 mM captopril or its diluent
(NaCl 0.9%) for 30 min at room temperature before the fourth
washing.
 
5-LO Product Analysis.
 
Incubations were stopped by adding
cold (0
 
8
 
C) methanol/acetonitrile (50/50; vol/vol) containing
12.5 ng each of 19-OH prostaglandin B
 
2
 
 and prostaglandin B
 
2
 
 as
internal standards to aliquots of cell suspensions and stored at
 
2
 
20
 
8
 
C until reverse phase HPLC (RP-HPLC) analysis. Denatured
samples were centrifuged at 2,000 
 
g
 
 for 10 min, and the superna-
tants were subjected to RP-HPLC using on-line extraction pro-
cedures as previously described for PMN suspensions in HBSS
(14) or samples containing plasma (15). LTB
 
4
 
, 6-
 
trans
 
 isomers of
LTB
 
4
 
, 
 
v
 
 oxidation metabolites of LTB
 
4
 
, and 5(S)-hydroxy-
6,8,11,14(E,Z,Z,Z)-eicosatetraenoic acid (5-HETE) were mea-
sured by photometry at 280 and 229 nm, using fixed wavelength
UV detectors. The lower limits of detection were 0.5 ng at 280
nm and 1 ng at 229 nm.
 
Analysis of Ado.
 
PMN incubations (1 ml) were stopped by
adding 100 
 
m
 
l of 22% TCA. NECA was added (10 ng/sample) as
an internal standard and the denatured cell suspensions were
placed at 
 
2
 
20
 
8
 
C for at least 30 min. The samples were then cen-
trifuged at 2,000 
 
g
 
 for 10 min and the supernatants were extracted
on Sep Pak Cartridges (3 cc, C-18 sorbent) as follows. The sam-
ples were loaded on the cartridges which were washed with wa-
ter; Ado was then eluted with 3.5 ml of methanol/water (50:50,
containing 0.1% acetic acid). The eluates were evaporated to dry-
ness using a Speed Vac evaporator. The residues were dissolved in
200 
 
m
 
l of methanol/water (25:75, containing 0.05% acetic acid).
The samples were analyzed by liquid chromatography–mass spec-
trometry using nebulizer-assisted electrospray ionization in the
positive mode and by monitoring the transitions m/z 309 and m/z
268 (protonated parent ions) to m/z 136 (protonated adenine),
corresponding to the loss of the carbohydrate moieties from
NECA and Ado. The samples (1–2 
 
m
 
l) were injected onto a C-18
column (Ultrasphere, 2 
 
3
 
 150 mm, 5-
 
m
 
 particles; Beckman, Ful-
lerton, CA) and eluted at a flow rate of 200 
 
m
 
l/min using metha-
nol/water (40:60, containing 0.1% acetic acid) as the mobile phase.
Ado was quantitated by extrapolating the measured Ado/NECA
ratio on a calibration curve generated from standard solutions
containing 1 ng NECA and 0–4 ng Ado in 5 
 
m
 
l. The limit of de-
tection for Ado was 
 
z
 
50 pg injected (signal to noise ratio 
 
>
 
5).
 
Results
 
Ado Concentrations in PMN Suspensions.
 
Isolated PMNs in
suspension in salt buffers have been reported to release Ado
at levels that influence their functions (12). We thus per-
formed measurements of endogenous Ado concentrations
in PMN suspensions under conditions used for the assess-
ment of leukotriene biosynthesis. After the centrifugation
and resuspension of PMNs in fresh buffers, aliquots were
removed for up to 60 min and the concentration of Ado
was measured. PMNs resuspended in HBSS or autologous
plasma released Ado in a time– and cell concentration–
dependent manner (Fig. 1). Cell-depleted plasma was found
to contain 30 
 
6
 
 3 nM (mean 
 
6
 
 SE, 
 
n
 
 
 
5
 
 6) of Ado. The
addition of 0.1 U Ado deaminase after the incubation of
2.0 
 
3
 
 10
 
7
 
 PMN/ml for 15 min in HBSS reduced the con-
centration of Ado within seconds to 
 
,
 
4 nM, and remained
below this level for up to 30 min. Stimulation of PMNs
with 0.6 
 
m
 
M platelet-activating factor (PAF) did not have
any effect on the levels of endogenous Ado (not shown).
 
LTB
 
4
 
 Biosynthesis in HBSS.
 
We first examined the effect
of endogenous Ado present in PMN suspensions in HBSS
on the synthesis of LTB
 
4
 
. Endogenous Ado was neutralized
using two different approaches; the addition of a selective
A
 
2a
 
 receptor antagonist, CSC (16; Fig. 2 
 
A
 
), or Ado deam-
inase (Fig. 2 
 
B
 
) to the incubation media. The pretreatment
of TNF-
 
a
 
/GM-CSF–primed neutrophils with increasing
concentrations of either CSC or Ado deaminase before
stimulation with 0.6 
 
m
 
M PAF resulted in a progressive en-
hancement of 5-LO product biosynthesis, as compared to
cells stimulated in the absence of CSC or Ado deaminase.
Figure 1. Time course of Ado accumulation in PMN suspensions.
Freshly isolated PMNs were resuspended in HBSS (A) or autologous
plasma (B) at concentrations of 5 3 106/ml (squares) or 20 3 106/ml (cir-
cles). At various time points, 1-ml aliquots of the cell suspensions were de-
natured with TCA and the Ado content was measured by liquid chroma-
tography–mass spectrometry. Results shown are the means 6 SD of
triplicate incubations from one experiment representative of three. Error
bars are not shown when smaller than symbols. 
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The stimulatory effect of Ado deaminase was fully reversed
by the addition of 1 
 
m
 
M CGS 21680, a selective A
 
2a recep-
tor agonist (17). Fig. 2 C illustrates typical HPLC profiles
of the 5-LO products generated by PMNs activated with
PAF in the presence or absence of CSC or Ado deaminase.
In the absence of PAF stimulation, the biosynthesis of
LTB4 was not detected.
LTB4 Biosynthesis in Plasma. We next examined whether
endogenous Ado also suppressed LTB4 biosynthesis by
PMNs resuspended in plasma. Stimulation of TNF-a/
LPS–primed PMNs with fMLP resulted in the biosynthesis
of only minimal amounts of LTB4 (Fig. 3 A). The addition
of Ado deaminase to the similarly primed PMN suspen-
sions before fMLP stimulation failed to further increase the
biosynthesis of LTB4. In contrast, the addition of both Ado
deaminase and rLTA4 hydrolase resulted in a marked en-
hancement of LTB4 biosynthesis. As observed with PMNs
treated with Ado deaminase alone, the addition of rLTA4
hydrolase alone failed to increase the synthesis of LTB4
upon fMLP stimulation. The effect of adding Ado deami-
nase and rLTA4 hydrolase to PMN suspensions in plasma
on LTB4 biosynthesis was mimicked by the addition of
RBCs, which are known to uptake extracellular Ado (18)
and contain LTA4 hydrolase activity (7; Fig. 3 B). That the
RBC LTA4 hydrolase was involved in the biosynthesis of
LTB4 was confirmed by a pretreatment of RBCs with cap-
topril, an inhibitor of LTA4 hydrolase (19), which resulted
in a near complete inhibition of the effect of RBCs. Simi-
larly, the involvement of RBCs in lowering extracellular
Ado was demonstrated by adding dipyridamole, an inhibi-
tor of Ado transport (18), to the incubation media 15 min
before fMLP stimulation. Dipyridamole also caused a
marked inhibition of LTB4 biosynthesis; that the inhibitory
effect of dipyridamole was the consequence of an accumu-
lation of Ado in the incubation media was assessed by the
coaddition of Ado deaminase, which completely restored
LTB4 biosynthesis to the level observed with RBCs (data
Figure 2. Effects of CSC and Ado deaminase treatment of PMN sus-
pensions on LTB4 biosynthesis. PMN suspensions in HBSS (107/ml) were
preincubated with 700 pM GM-CSF 1 1.2 nM TNF-a for 30 min, and
then treated with various concentrations of CSC (A) or Ado deaminase
(B) for 5 min and stimulated with 0.6 mM PAF. After 10 min of incuba-
tion in the presence (or absence) of PAF, incubations were stopped and
5-LO products were measured by RP-HPLC. In B, CGS 21680 was
added at the concentration of 1 mM. Data are the means (6 SD) of tripli-
cate incubations from one experiment representative of three. (C) RP-
HPLC profiling of 5-LO products generated by TNF-a/LPS–primed
PMN suspensions stimulated (or not, control) with PAF, with or without
earlier pretreatment with either 0.1 U deaminase Ado or 1 mM CSC.
Conditions were as indicated for A and B; 5(S)-hydroxy-6,8,11,14(E,Z,Z,Z)-
eicosatetraenoic acid (5-HETE) was not detectable in all conditions
tested. Amounts of LTB4 indicated represent the sum of 20-OH LTB4,
20-COOH LTB4, and LTB4. PGB2, prostaglandin B2; ADA, adenosine
deaminase.
Figure 3. Effect of exogenous
LTA4 hydrolase, Ado deaminase,
and RBCs on the biosynthesis of
LTB4 by PMNs in plasma. (A)
PMN (5 3 106) in suspension in
autologous plasma (0.5 ml) were
treated with 1.2 nM TNF-a and
1  mg/ml LPS for 30 min at
378C. 10 ml of the preparation of
rLTA4 hydrolase (see Materials
and Methods) and/or 4 U of
Ado deaminase (or its diluent,
NaCl 0.9%) were added (per
milliliter of incubation media) 1
and 5 min, respectively, before
stimulation with 1 mM fMLP.
After 15 min of stimulation, the
incubations were stopped and
LTB4 production was measured
by RP-HPLC. (B) PMNs (5 3
106) in suspension in autologous
plasma (0.5 ml) were treated with
1.2 nM TNF-a and 1 mg/ml LPS
for 30 min at 378C. RBCs (0.5 ml of packed cells) treated or not with
captopril (see Materials and Methods) were next added to PMNs in
plasma; the incubation media were further treated or not with 30 mM
dipyridamole for 25 min at 378C, and then stimulated with 1 mM fMLP
for 15 min. LTB4 biosynthesis was measured by RP-HPLC. Results
shown are the means 6 SD of triplicate incubations from one experiment
representative of three. LTA4-H, LTA4-hydrolase; DIPY, dipyridamole;
CAPT-RBC, captopril-treated red blood cells; ADA, Ado deaminase.1404 Regulation of LTB4 Synthesis by Adenosine
not shown). The pretreatment of RBCs with captopril and
addition of dipyridamole inhibited the biosynthesis of
LTB4 to the level observed in the absence of RBCs.
Discussion
We recently reported that Ado and analogues (particularly
A2a agonists) are potent inhibitors of LTB4 biosynthesis in
whole blood, as well as in isolated PMNs and monocytes
(11). It is also recognized that Ado accumulates in PMN
suspensions (12). These observations led us to hypothesize
that endogenous Ado present in PMNs suspensions might
exert a suppressive effect on the biosynthesis of LTB4.
Measurements of Ado concentrations in PMN incubation
media (HBSS and plasma) clearly indicated that after 15–30
min of incubation in all experimental conditions tested,
Ado reaches concentrations (25–400 nM; Fig. 1) likely to
severely impact LTB4 synthesis, given the IC50 of 80 and 60
nM measured previously for the inhibition of LTB4 synthe-
sis in blood (11) and HBSS (our unpublished data), respec-
tively. Accordingly, we found that the removal of endoge-
nous Ado using Ado deaminase or the blockade of its effect
with the A2a receptor antagonist CSC, strikingly increased
the biosynthesis of LTB4 in response to ligand stimulation.
For PMNs activated in the presence of plasma, however,
the addition of Ado deaminase to the incubation media was
not efficient in increasing the biosynthesis of LTB4. On the
basis of the recent report that activated PMNs release LTA4
in the extracellular milieu (6), we postulated that LTB4
biosynthesis by PMN suspensions in plasma was inhibited
by the trapping of its precursor LTA4 by the plasma pro-
teins, which prevented the uptake and further metabolism
of LTA4 by the PMN LTA4 hydrolase. Indeed, it has been
previously shown that LTA4 binds to serum albumin,
which results in a dramatic increase of its half-life (20). Ac-
cordingly, the addition of rLTA4 hydrolase and Ado deami-
nase, but not of either enzyme alone, resulted in a signifi-
cant increase of LTB4 biosynthesis by PMNs in plasma.
Our results therefore demonstrate that LTB4 biosynthesis
by PMNs in plasma is limited by the inhibitory constraint
generated by endogenous Ado which prevents the forma-
tion of LTA4. The removal of Ado (using Ado deaminase)
is, however, insufficient to allow efficient LTB4 biosynthe-
sis since LTA4 released by PMNs is bound to plasma pro-
teins. The addition of rLTA4 hydrolase in PMN suspen-
sions in plasma drastically accelerates and enhances the
generation of LTB4. The mechanism by which Ado sup-
presses LT synthesis in PMNs remains to be defined. We
can exclude, however, the idea that the inhibitory effect of
Ado on LT biosynthesis in PMN results from an effect of
the nucleoside on the release or uptake of LTA4. Indeed, in
the experimental system used (Fig. 2), the formation of
LTB4 (and LTB4 metabolites) depends on the reuptake of
extracellular LTA4 which is then converted by the cytosolic
LTA4 hydrolase (6). Therefore, inhibition of initial LTA4
release by the activated PMNs would be expected to facili-
tate LTB4 formation, whereas inhibition of extracellular
LTA4 uptake would result in the formation of the 6-trans
isomers (nonenzymic hydrolysis products) of LTB4, which
was not observed in our experiments. Another possible site
of action of Ado in the regulation of LTB4 biosynthesis
could be at the level of the conversion of LTB4 to its v ox-
idation products. However, as seen in Fig. 2 C, endoge-
nous Ado suppresses the formation of both LTB4 and 20-
OH LTB4, the sum of LTB4, and its metabolites being
two- to threefold greater in incubations performed in pres-
ence of Ado deaminase or CSC. Interestingly, previous studies
have shown that elevated extracellular concentrations of
Ado inhibits external Ca21 influx in PMNs stimulated by
either PAF or fMLP (21). Since LTB4 biosynthesis is highly
dependent on ligand-stimulated Ca21 influx (22), it is
therefore conceivable that the inhibitory effects of Ado
might be related to the modulation of arachidonate release
and/or 5-LO activation, both of which are Ca21 dependent
(22, 23). Studies are in progress to assess this hypothesis.
Another finding of the current study is the involvement
of a dual mechanism in the regulation of the biosynthesis of
LTB4 by RBCs. Indeed, RBCs have previously been
shown to enhance the biosynthesis of LTB4 through the
transcellular metabolism of LTA4 by RBC LTA4 hydrolase
(8). However, the results of our studies with PMN in
plasma suggested that the presence of RBC LTA4 hydrolase
cannot fully account for the increased production of LTB4,
and that the reported capacity of RBCs to efficiently take
up Ado (18) may contribute to the ability of RBCs to en-
hance the synthesis of LTB4 by ligand-stimulated PMNs in
plasma. In fact, both RBC-mediated events proved to be
determinant in the stimulatory effect of RBCs since both
captopril, an inhibitor of LTA4 hydrolase, and dipyridamole,
an inhibitor of adenosine transport, efficiently reversed the
effect of RBCs on LTB4 synthesis, in full agreement with
the data obtained by the simultaneous addition of LTA4
hydrolase and Ado deaminase to PMNs activated in plasma.
The fact that endogenous Ado exerts a negative regula-
tion of LTB4 biosynthesis by ligand-stimulated PMNs has
led to an underestimation of the potential of this cell type
to respond to stimulation by physiological agonists such as
fMLP and PAF (24) and has also contributed to the genera-
tion of controversial data concerning the ability of PMNs
to produce LTs in response to such stimuli. Indeed, it is
likely that differences in experimental conditions used by
different investigators, such as PMN concentration and
preincubation temperature and time, directly impact on
Ado concentration in the cell suspensions and therefore, on
cell responsivity to the stimuli. Moreover, while LTB4 syn-
thesis by PMNs stimulated by soluble agonists such as
fMLP and PAF is highly sensitive to inhibition by Ado, the
synthesis of LTB4 by PMNs stimulated by the ionophore
A23187 is much less sensitive to Ado inhibition (11). It
seems important to point out that in an in vivo context, the
inhibition of PMN LTA4 biosynthesis by Ado likely has
consequences not only on LTB4 formation, but also on the
biosynthesis of cysteinyl LTs and lipoxins, since these may
be generated, at least in part, from the transcellular metabo-
lism of PMN-derived LTA4 by endothelial cells (25) and
platelets (26).1405 Krump et al. Brief Definitive Report
In summary, the current study demonstrates the regula-
tory role of endogenous Ado on ligand-stimulated LT bio-
synthesis by PMNs and strongly emphasizes that an ele-
vated level of endogenous Ado in physiological settings can
have profound consequences on the ability of PMNs to
produce LTA4, the direct precursor of the lipid mediators
LTB4, LTC4, and lipoxins, which have been shown to
modulate phagocyte functional responses and inflammatory
events. Our observations also support the recently pro-
posed concept that Ado is a natural antiinflammatory agent
(10). Indeed, it has become increasingly apparent that the
antiinflammatory mechanism of methotrexate and sulfasala-
zine, two potent antiinflammatory drugs, involves an in-
crease of Ado concentration at sites of inflammation (10,
27). Most importantly, these studies showed that leukocyte
accumulation at inflammatory sites was diminished and that
these effects of the drugs could be antagonized by Ado
deaminase or Ado receptor antagonists. In view of the abil-
ity of Ado to suppress LTB4 biosynthesis, it is tempting to
speculate that the mechanism by which these antiinflam-
matory agents act might include the inhibition of LTB4-
dependent extravasation of leukocytes. Further studies are
needed to characterize the consequences of increasing Ado
levels on LTB4-mediated inflammatory processes. Finally,
taken together, these recent observations and the previ-
ously reported inhibitory effects of Ado on PMNs and
monocyte functions support that A2a receptor agonists or
agents that can regulate Ado biosynthesis, metabolism, or
transport may represent a novel class of potent antiinflam-
matory agents.
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